Bernstein Harold sold $426K of MAZE
Bernstein Harold (President, R&D & CMO) sold 16,141 shares of Maze Therapeutics, Inc. (MAZE) at $26.36 ($0.43M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Provides primary disclosure of insider activity; limited trading relevance.
Market read
Routine insider sale with modest size; minimal impact on stock.
What to watch
Potential upcoming dilution events or financing activities not disclosed.
Background
Form 4 filing reveals insider transaction under a 10b5-1 plan.
Ticker impact
President of R&D & CMO sold 16,141 shares for $425.5K via 10b5-1 plan, leaving zero holdings.
Minor downward pressure, likely negligible on market price.
Sale size is modest relative to market cap and executed under a pre-arranged plan, reducing informational value.
Market effects
No broader sector impact; typical insider transaction.
Limited to US biotech sector, negligible.
Low
Counterpoint
Sale could be a red flag if insider confidence wanes, but could also be routine liquidity need.
Key entities
- OfficerBernstein Harold
President, R&D & CMO of Maze Therapeutics